Table 2.
List of phase 1 clinical trials currently recruiting patients for ICI combined with other interventions (data retrieved from https://clinicaltrials.gov/; accessed on 22 February 2023).
| Serial No. | National Clinical Trial (NCT) Number | Conditions | Interventions | Enrollment | Proposed Completion |
|---|---|---|---|---|---|
| 1 | NCT05303493 | NSCLC Stage IV|Melanoma Stage IV|Unresectable Melanoma|Advanced Non-Small Cell Lung Cancer | Biological: Camu Camu Capsules (Camu Camu powder encapsulated (500 mg each) + ICI | 45 | 15-Apr-27 |
| 2 | NCT05430009 | Liver Metastases|Non-small Cell Lung Cancer | Radiation: Liver SBRT|Drug: Pembrolizumab | 12 | 15-Jun-26 |
| 3 | NCT04290546 | Squamous Cell Carcinoma of the Head and Neck|Recurrent Head and Neck Squamous Cell Carcinoma | Drug: Interleukin-15 Superagonist (N-803)|Biological: CIML NK cell Infusion|Drug: Ipilimumab | 12 | 31-Dec-23 |
| 4 | NCT05497453 | Hepatocellular Carcinoma|Solid Tumor|Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent|Hepatocellular Cancer|Liver Cancer|Liver, Cancer of, Non-Resectable | Drug: OTX-2002|Drug: Tyrosine kinase inhibitor One|Drug: Tyrosine kinase inhibitor Two|Drug: Checkpoint Inhibitor, Immune | 190 | Dec-28 |
| 5 | NCT05338775 | Relapsed/Refractory Multiple Myeloma | Drug: Talquetamab|Drug: Teclistamab|Drug: PD-1 Inhibitor | 152 | 15-Oct-25 |
| 6 | NCT02557321 | Melanoma | Drug: PV-10|Drug: Pembrolizumab | 192 | Nov-24 |
| 7 | NCT04187404 | Adrenocortical Carcinoma|Pheochromocytoma|Paraganglioma | Biological: EO2401|Biological: Nivolumab|Biological: EO2401 and nivolumab | 120 | 30-Dec-24 |
| 8 | NCT05089370 | Malignant Melanoma | Combination Product: Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab | 30 | Jul-26 |
| 9 | NCT04247165 | Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer | Drug: Gemcitabine|Drug: Nab-paclitaxel|Drug: Nivolumab|Drug: Ipilimumab|Radiation: SBRT | 40 | Feb-24 |
| 10 | NCT05598853 | Leptomeningeal Metastasis|Non-small Cell Lung Cancer Stage IV|Melanoma Stage IV | Drug: intrathecal nivolumab and intrathecal ipilimumab | 26 | Apr-25 |
| 11 | NCT04003649 | Recurrent Glioblastoma|Refractory Glioblastoma | Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Biological: Ipilimumab|Biological: Nivolumab|Other: Quality-of-Life Assessment|Other: Questionnaire Administration | 60 | 31-Dec-24 |